Search Results

Business

Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focused specialty pharmaceutical company, for Cantrixil (TRX-E-002-1)

March 1, 2021

·

2 min read

Policy

OASMIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Oasmia Pharmaceutical AB To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM).

June 28, 2019

·

1 min read

Business

Elevar Therapeutics Acquires Global Rights to European Approved Apealea® from Oasmia Pharmaceutical

Elevar Therapeutics, Inc., a fast-growing biopharmaceutical company focused on promising therapies for unmet medical needs in cancer, announced today an agreement with Swedish-based Oasmia Pharmaceutical AP to obtain global rights for Apealea®, except in Nordics, Russia , and certain countries in Eastern Europe.

March 25, 2020

·

4 min read

Deals

SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: September 27, 2019

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Oasmia securities between October 23, 2015 through July 9, 2019, both dates inclusive.

August 1, 2019

·

2 min read

Policy

ROSEN, A HIGHLY RANKED LAW FIRM, Reminds Oasmia Pharmaceutical AB Investors of September 27th Deadline in First Filed Securities Class Action Commenced by the Firm

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Oasmia Pharmaceutical AB from October 23, 2015 through July 9, 2019, inclusive of the important September 27, 2019 lead plaintiff deadline in the securities class action commenced by the firm.

August 31, 2019

·

3 min read

Issuance Of Warrants In Oasmia

June 21, 2017

·

2 min read

The Oasmia Annual Report Is Now Published

July 7, 2017

·

1 min read

Policy

Oasmia Pharma Receives Marketing Approval for Paclical in Kazakhstan

Paclical will be sold through Hetero Group and is planned to be launched during the first half of 2018.

December 11, 2017

·

1 min read

Business

Sales Focus For Oasmia

June 8, 2016

·

1 min read

FDA

Oasmia Receives Market Approval For Its Anti-Cancer Drug Doxophos In Russia

August 10, 2017

·

2 min read